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ABSTRACT
Amain clinical parameter of COVID-19 pathophysiology is hypoxia. Here we show that hypoxia decreases the attachment
of the receptor-binding domain (RBD) and the S1 subunit (S1) of the spike protein of SARS-CoV-2 to epithelial cells. In
Vero E6 cells, hypoxia reduces the protein levels of ACE2 and neuropilin-1 (NRP1), which might in part explain the
observed reduction of the infection rate. In addition, hypoxia inhibits the binding of the spike to NCI-H460 human
lung epithelial cells by decreasing the cell surface levels of heparan sulfate (HS), a known attachment receptor of
SARS-CoV-2. This interaction is also reduced by lactoferrin, a glycoprotein that blocks HS moieties on the cell surface.
The expression of syndecan-1, an HS-containing proteoglycan expressed in lung, is inhibited by hypoxia on a HIF-1α-
dependent manner. Hypoxia or deletion of syndecan-1 results in reduced binding of the RBD to host cells. Our study
indicates that hypoxia acts to prevent SARS-CoV-2 infection, suggesting that the hypoxia signalling pathway might
offer therapeutic opportunities for the treatment of COVID-19.
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Introduction
By mid-May of 2021, SARS-CoV-2 has infected over
160 million people and caused >3.3 million deaths.
Until now, more than 1200 million vaccines have
been administered. However, the efficacy of available
vaccines against emerging variants remains unclear
[1,2]. Therefore, the need of effective treatments to
prevent the infection or to manage the disease in
severe cases of COVID-19 remains an urgent medical
need.
The spike protein of SARS-CoV-2 interacts with
the angiotensin-converting enzyme 2 (ACE2), a key-
receptor widely expressed on the respiratory tract,
through the receptor-binding domain (RBD) [3–5].
Other factors such as neuropilin-1 (NRP1) [6,7] and
the transmembrane protease serine 2 (TMPRSS2) [8]
contribute to the entry of SARS-CoV-2 into host
cells. Another layer of interaction between the virus
and the host that facilitates viral entry is the
attachment of the spike protein to cellular heparan
sulfate (HS) [5]. HS is part of the cellular glycocalyx
and decorates the HS-containing proteoglycans
(HSPGs). The family of syndecans are HSPGs
expressed on several cell types and organs [9], being
syndecan-1 the most relevant in terms of expression
in the lung [10]. The interaction between the spike
and HS can be efficiently blocked by lactoferrin [11].
A common feature of COVID-19 patients is mod-
erate to severe hypoxia [12–15]. Disease severity cor-
relates with the level of naturally occurring anti-
SARS-CoV-2 antibodies in serum [16], and patients
with severe disease are characterized by low oxygen
saturation that often results in the need for oxygen
supplementation [17]. Currently, the impact of
hypoxia on SARS-CoV-2 infectivity and COVID-19
pathogenesis is unclear, but there are emerging indi-
cations that low oxygen concentrations might prevent
infection or disease severity [18,19]. This notion is
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supported, in part, by the fact that epidemiological
data indicate that COVID-19 severity decreases in
high altitude areas [20].
There is evidence that hypoxia regulates the
expression of ACE2, but the underlying mechanisms
and impact on physiology and disease remain contro-
versial. Previous studies have demonstrated that regu-
lation of ACE2 expression by hypoxia is context-
specific and cell type- and time-dependent [21–25].
Elucidating these mechanisms in lung epithelial cells
would help to understand the cellular susceptibility
to infection by SARS-CoV-2 under limited oxygen
availability. Additionally, the members of the synde-
can family, the main cellular HSPGs, are also differen-
tially regulated by hypoxia. For example, the
expression of syndecan-1 in the lungs is reduced
under hypoxia [26,27].
Cell responses to hypoxia are mediated by the
family of hypoxia inducible factors (HIF). COVID-
19 disease leads to the accumulation of HIF in the
lung, providing a molecular link between SARS-
CoV-2 infection and hypoxia in patients with severe
disease [28]. Our hypothesis is that hypoxia modulates
the expression of entry receptors and attachment fac-
tors on host cells. In this context, elucidating the
underlying mechanisms of this regulation could lead
to the development of novel therapeutic strategies
for the management of COVID-19, including those
targeting the hypoxia response pathway.
Materials and methods
Cell culture
The NCI-H460 human lung epithelial cell line was
obtained from DSMZ (German Collection of Microor-
ganisms and Cell Lines Cat#: ACC737) and cultured
in RPMI medium 1640 GlutaMAX (Gibco Cat#:
61870044) according to standard culture protocols.
Vero E6 monkey kidney cells (ATCC Cat#: CRL-
1586) were kindly provided by Nicola G.A. Abrescia
(CIC bioGUNE) and cultured in MEM (Gibco Cat#:
31095-029). HEK 293T cells (Takara Bio Inc. Cat#:
632180) were cultured in DMEM (Gibco Cat#: 41966-
029). Media were supplemented with 10% FBS (Thermo
Fisher Cat#: 10270106) and 1% Penicillin–Streptomycin
(Thermo Fisher Cat#: 15140122). Hypoxia cultures were
performed at 1% O2 and 5% CO2 in an In Vivo2 400
hypoxia station (Ruskinn Technologies).
Lactoferrin assay
Binding of RBD to the surface of cells was measured
by flow cytometry after incubation with increasing
doses of human lactoferrin (0, 1, 5 and 10 mM)
(Sigma Aldrich Cat#: L1294) in a final volume of
100 μL of culture medium. The incubation was done
for 45 min in a cell incubator with standard conditions
(37°C, 21% O2 and 5% CO2).
Assessment of binding of RBD and S1 to the cell
surface
After culture, cells were collected with cell dissociation
buffer (Thermo Fisher Cat#: 13151-014), distributed
in 96-well polystyrene conical bottom plates (Thermo
Fisher Cat#: 249570) and washed with PBS (Fisher
BioReagents Cat#: BP3994) containing 0.5% BSA
(Sigma Aldrich Cat#: A9647) (blocking buffer) fol-
lowed by centrifugation and the supernatant was dis-
carded. Cells were incubated with biotinylated S1
(Acrobiosystems Cat#: S1N-C82E8) or RBD (Acrobio-
systems Cat#: SPD-C82E9) proteins (20 μg/mL) in
50 μL of blocking buffer for 30 min at 4°C. After incu-
bation, cells were centrifuged, washed with 200 μL of
blocking buffer, centrifuged again and incubated
with streptavidin-PE (Thermo Fisher Cat#: 12-4317-
87) diluted in 100 μL of blocking buffer (1:200
dilution). Finally, cells were centrifuged and washed
twice and resuspended in blocking buffer with DAPI
(Invitrogen Cat#: D1306) for acquisition in the flow
cytometer. All centrifugation steps were performed
at 300g for 5 min (4°C).
Generation of pseudotyped lentiviral particles
Pseudotyped lentiviral particles were generated by
transfecting HEK 293T cells as described in Crawford
et al. [29], using a five-plasmid third-generation sys-
tem kindly provided by Dr Jesse D. Bloom (Fred
Hutchinson Cancer Research Center) and Dr Jean-
Philippe Julien (University of Toronto). Confluent
HEK 293T cells (50–70%) were transfected with plas-
mids encoding for the lentiviral backbone (containing
a CMV promoter to express ZsGreen) (NR-52520,
5.79 µg), the SARS-CoV-2 spike protein (NR-52514,
1.97 µg), HDM-Hgpm2 (NR-52517, 1.27 µg), pRC-
CMV-Rev1b (NR-52519, 1.27 µg) and HDM-tat1b
(NR-52518, 1.27 µg) using the jetPEI kit (Polyplus-
transfection Cat#: 101-10N). 48 h after transfection,
viruses were harvested from the supernatant, filtered
through a 0.45 µm filter (VWR Cat#: 514-0063), con-
centrated using Lenti-X Concentrator (Takara Bio Inc.
Cat#: 631231) and stored in PBS at −80°C until use.
Titration of the pseudotyped lentiviral particles
and infection of Vero E6 cells
Viral titration was performed in Vero E6 cells as
described in Crawford et al. [29]. For single-infection
experiments, 150,000 cells were seeded in 6-well plates
and cultured overnight in normoxia (21% O2) and incu-
bated for additional 24 h under normoxia or hypoxia
(1% O2). After that, cells were incubated with the
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pseudotyped lentiviral particles (MOI: 0.1) for 48 h
under normoxic conditions. The infected cells expressed
ZsGreen, allowing their detection by flow cytometry.
Deletion of HIF-1α and syndecan-1 in NCI-H460
cells via CRISPR/Cas9
Deletion of HIF-1α in NCI-H460 cells was performed
using a pool of two sgRNAs from Synthego (sgRNA
sequences: gaugguaagccucaucacag and guuuuccaaa-
cuccgacauu) and the TrueCut Cas9 protein v2 (Invitro-
gen Cat#: A36497). Deletion of syndecan-1 was
performed using the following TrueGuide Synthetic
sgRNAs from Invitrogen: CRISPR913712_SGM and
CRISPR913714_SGM. RNP-complexes were generated
with 7.5 pmol of Cas9, 7.5 pmol of the sgRNA-1 and
7.5 pmol of the sgRNA-2. RNP-complexes were intro-
duced into cells using the Lipofectamine CRISPRMAX
Cas9 Transfection reagent (Invitrogen Cat#:
CMAX00001) and Opti-MEM reduced serum medium
(Gibco Cat#: 31985062) following the Pub. No.
MAN0017058 by Invitrogen (pages 5 and 6). A non-
targeting sgRNA that does not recognize any sequence
in the human genome was used as a negative control
(Invitrogen Cat#: A35526). The deletion efficiency of
HIF-1α and syndecan-1 proteins was measured by wes-
tern blot and flow cytometry, respectively, and the pool
of edited cells was used for downstream experiments.
Flow cytometry
Cells were collected, washed with blocking buffer and
incubated with fluorochrome-conjugated antibodies
(1:100 dilution in blocking buffer) against syndecan-
1 (BD Biosciences Cat#: 565943), syndecan-2 (R&D
Systems Cat#: FAB2965P), syndecan-3 (R&D Systems
Cat#: FAB3539A) and syndecan-4 (R&D Systems
Cat#: FAB291819) for 15 min at 4°C. Total cellular
HS was measured by flow cytometry after incubation
for 30 min at 4°C with an anti-HS primary antibody
(Amsbio Cat#: 370255-S; clone F58-10E4) (1:200
dilution in blocking buffer). After that, cells were cen-
trifuged, washed and incubated with an anti-IgM
FITC-conjugated secondary antibody (Miltenyi Biotec
Cat#: 130-095-906) (1:500 dilution in blocking buffer).
Finally, cells were centrifuged, washed twice and
resuspended in 200 μL of blocking buffer in the pres-
ence of 7-AAD (BD Biosciences Cat#: 51-68981E) or
DAPI (Invitrogen Cat#: D1306) to discriminate alive
cells. Cells were acquired on a FACSymphony cyt-
ometer (BD Biosciences). The results were analysed
using FlowJo version 10 (BD Biosciences).
Quantitative PCR
Total RNA was isolated using the NucleoSpin RNA kit
(Macherey–Nagel Cat#: 740955.250). The cDNA was
synthesized by RT–PCR from 1 μg of purified RNA
with theM-MLV reverse transcriptase (Thermo Fisher
Cat#: 28025-013) and random primers (Thermo
Fisher Cat#: 58875). Quantitative PCR (Q-PCR) reac-
tions were conducted in triplicate on a ViiA 7 Real-
Time PCR system (Thermo Fisher) from 1 μL of
cDNA using the PerfeCTa SYBR Green SuperMix
reagent (Quantabio Cat#: 95056-500) and gene-
specific primers. The amplification programme con-
sisted of initial denaturation at 95°C for 3 min fol-
lowed by 40 cycles of denaturation at 95°C for 15 s,
annealing at 60°C for 60 s and extension at 72°C for
60 s. Data were analysed using the QuantStudio soft-
ware version 1.3 (Thermo Fisher). The relative
quantification in gene expression was determined
using the 2–ΔΔCt method by using the RPLP0 gene as
a housekeeping gene (forward: 5′-CGACCTG-
GAAGTCCAACTAC-3′ and reverse: 5′-ATCTGCTG-
CATCTGCTTG-3′). PGK1, a HIF-1α target gene, was
used as a control for hypoxia (forward: 5′-
CCGCTTTCATGTGGAGGAAGAAG-3′ and reverse:
5′-CTCTGTGAGCAGTGCCAAAAGC-3′). Primer
sequences for measuring ACE2 and SDC1 expression
on human NCI-H460 cells were previously described
by Ma et al. [30] and Reynolds et al. [31], respectively.
As these oligos presented several mismatches with the
corresponding genes on the reference genome of the
African green monkey, we designed the following pri-
mers to amplify ACE2 from Vero E6 cells (forward: 5′-
AGCACTCACGATTGTTGGGA-3′ and reverse: 5′-
CCACCCCAACTATCTCTCGC-3′).
Western blot
Total cell lysates were collected using RIPA buffer and
quantified with the BCA Protein Assay kit (Thermo
Fisher Cat#: 23227). Samples were mixed with LDS
sample buffer (Invitrogen Cat#: NP0007) containing
DTT, boiled for 15 min, separated in a 4–15% Mini-
PROTEAN TGX precast protein gels (BioRad Cat#:
4561083) and transferred to a 0.2 μm PVDF mem-
branes (BioRad Cat#: 1704156) using a Trans-Blot
Turbo transfer system (BioRad). PageRuler protein
ladder (Thermo Fisher Cat#: 26619) was used to esti-
mate the molecular weight of the proteins. The mem-
branes were blocked for 1 h in 5% skim milk
(Millipore Cat#: 70166) and 0.5% Tween-20 (Sigma
Aldrich Cat#: 9005-64-5) diluted in PBS. The mem-
branes were probed overnight at 4°C with primary
antibodies diluted in PBS containing 5% BSA and
0.5% Tween-20, washed five times with PBS (contain-
ing 0.5% Tween-20), incubated for 1 h at RT with the
corresponding secondary HRP-conjugated antibodies
(1:5000 diluted in 5% skim milk and 0.5% Tween-20
diluted in PBS) and washed for five additional times.
The membranes were probed with antibodies against
HIF-1α (Novus Biologicals Cat#: NB100-449), ACE2
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(Bioss antibodies Cat#: bsm-52614R), NRP1 (Novus
Biologicals Cat#: NBP2-67539), TMPRSS2 (Novus
Biologicals Cat#: NBP3-00492), β-actin (Cell Signal-
ling Cat#: D6A8) and β-tubulin (Thermo Fisher
Cat#: MA5-16308). HRP-conjugated secondary anti-
bodies against mouse (Cat#: S301677076S) and rabbit
(Cat#: S301677074S) were obtained from Cell Signal-
ling. Chemiluminescence detection was performed
using Clarity Max Western ECL Substrate (BioRad
Cat#: 170506) on an iBright system (Invitrogen).
Band densitometry was performed using ImageJ
(https://imagej.nih.gov/ij/).
Statistics
Statistical analyses were performed using GraphPad
Prism version 8.0. The test applied in each panel is
specified on the figure legends.
Results
Hypoxia reduces the binding of the SARS-CoV-2
spike to epithelial cells
In order to understand if hypoxia could affect the cel-
lular binding capacity of the SARS-CoV-2 spike
protein, we subjected Vero E6 cells or human lung epi-
thelial cells (NCI-H460) to different oxygen concen-
trations (21% O2 or 1% O2) and measured the
binding ability of the receptor-binding domain
(RBD) and the S1 subunit (S1) of the spike protein
to the surface of these cells in vitro. Figure 1 shows a
significant decrease in the binding of RBD and S1
after culturing Vero E6 (Figure 1(a)) or NCI-H460
(Figure 1(b)) cells under hypoxia (1% O2) compared
to normoxia (21% O2).
Hypoxia decreases ACE2 and NRP1 protein
levels on Vero E6 cells
To further explore the mechanism underlying the
observed reduced binding of the spike under hypoxia,
we assessed ACE2 gene and protein expression on
Vero E6 and NCI-H460 cells by Q-PCR and western
blot, respectively. Vero E6 cells, but not NCI-H460
cells, present detectable levels of ACE2 transcripts
(Figure 2(a)). Accordingly, ACE2 protein is only
detectable on Vero E6 cells (Figure 2(b)), suggesting
that the observed binding of the spike to the surface
of NCI-H460 cells is ACE2-independent. We then
explored if hypoxia modulates ACE2 expression on
Vero E6 cells. Hypoxia culture results in a transient
accumulation of HIF-1α and upregulation of the
expression of ACE2 (Figure 2(b,c)). After 48 h of
exposure to a limited oxygen supply, the level of
ACE2 protein on Vero E6 cells is significantly reduced
(Figure 2(b)). On a similar manner, we measured the
expression of other important factors that mediate
the initial steps of SARS-CoV-2 infection: NRP1 and
TMPRSS2. NRP1 (but not TMPRSS2) is significantly
reduced on Vero E6 cells after culture for 48 h under
hypoxia (Figure 2(d)), as previously described by
Casazza et al. [32] on the hypoxic tumour microenvir-
onment. NCI-H460 cells do not express detectable
levels of NRP1.
Hypoxia prevents the infection of Vero E6 cells
with pseudotyped viral particles expressing the
spike protein of SARS-CoV-2
We then assessed the influence of oxygen availability
on the infection capacity of pseudotyped lentiviral
particles that express the full-length spike of SARS-
CoV-2. Vero E6 cells exposed to hypoxia show a sig-
nificant decrease in the rate of infection (Figure 3
(a)) compared to normoxia. NCI-H460 cells, which
lack expression of ACE2 and NRP1 (Figure 2(b,d)),
are not amenable to infection (Figure 3(b)).
Lactoferrin blocks the binding of RBD to the
surface of epithelial cells
Recently, it has been demonstrated that the spike of
SARS-CoV-2 can bind to HS expressed on the host
cell surfaces [5]. We reasoned that this phenomenon
might explain the observed binding of RBD to NCI-
H460 epithelial cells in the absence of ACE2 and
NRP1. To confirm this interaction, we blocked cellular
HS with human lactoferrin, a natural glycoprotein that
binds to HS and presents antiviral activity against cor-
onaviruses [11,33]. Figure 4 shows that lactoferrin was
able to reduce the attachment of the RBD of SARS-
CoV-2 to Vero E6 (Figure 4(a)) and NCI-H460
(Figure 4(b)) cells in a dose-dependent manner. Inter-
estingly, the degree of blockade by lower doses of lac-
toferrin was higher on NCI-H460 compared to Vero
E6 cells.
Hypoxia decreases the total level of heparan
sulfate on the surface of epithelial cells
Considering that cellular HS mediates the binding of
RBD in NCI-H460 cells lacking the expression of
ACE2 and NRP1, we explored if this interaction was
altered by hypoxia. Hypoxia significantly decreases
the total level of cellular HS present on Vero E6 cells
(Figure 5(a)) and, to a higher extent, on NCI-H460
cells (Figure 5(b)). The syndecan family is a major
contributor to the pool of HS on the surface of cells.
In this context, we assessed the expression levels of
syndecan-1, syndecan-2, syndecan-3 and syndecan-4
on NCI-H460 cells. We found that syndecan-1 and
syndecan-3 are the main syndecans expressed on
1068 E. Prieto-Fernández et al.
this cell model and that hypoxia significantly reduces
their expression at protein level (Figure 5(c)).
Hypoxia reduces the binding of RBD to NCI-
H460 epithelial cells by downregulating
syndecan-1 expression on a HIF-1α-dependent
mechanism
Based on the finding that syndecan-1 is the most
abundantly expressed syndecan on NCI-H460 cells
(Figure 5(c)), we sought to ascertain its role in the
attachment of the spike protein to host cells. Figure
6(a) shows that NCI-H460 cells expressing high levels
of syndecan-1 capture higher amounts of RBD com-
pared to cells expressing low levels of syndecan-1.
To further demonstrate the binding of RBD to synde-
can-1, we generated a cell line with reduced expression
of syndecan-1 via CRISPR/Cas9 (SDC1-KO). A pool
of SDC1-edited cells binds less RBD compared to con-
trol NCI-H460 cells (Figure 6(b)). Given that HIF-1α
is the main transcriptional mediator of the response
to hypoxia, we checked if it was responsible for the
observed downregulation of syndecan-1 under
hypoxia (Figure 5(c) and Figure 6(c)). To this end,
we generated HIF-1α deficient NCI-H460 cells via
CRISPR/Cas9 (Figure 6(d)). Deletion of HIF-1α on
NCI-H460 cells partially rescued the observed inhi-
bition of syndecan-1 expression under hypoxia
(Figure 6(e)), resulting in a marked increase in the
total levels of cellular HS (Figure 6(f)). Consequently,
the level of RBD binding to HIF1-KO cells under
hypoxia was higher than in control HIF-1α competent
cells (Figure 6(g)).
Discussion
COVID-19 disease is associated with hypoxia
[12,28,34], which results in decreased oxygen avail-
ability for tissues. This phenomenon affects the sus-
ceptibility of host cells to viral infections [35] and
shapes immune responses [36]. Here, we describe
the binding ability of the spike of SARS-CoV-2 to
epithelial cells cultured under different oxygen con-
centrations. We show that hypoxia inhibits the
binding of the RBD and the S1 subunit of the
spike of SARS-CoV-2 to host cells by modulating
the expression of several entry and attachment
factors.
Figure 1. Hypoxia reduces the binding of the SARS-CoV-2 spike to epithelial cells. (a and b) Binding of the receptor-binding
domain (RBD) (left) or S1 subunit (S1) (right) to Vero E6 (a) (n = 3 independent experiments, unpaired t test) or NCI-H460 (b)
(n = 2 independent experiments, unpaired t test) cells cultured under normoxia (21% O2) or hypoxia (1% O2) for 24 and 48 h,
measured by flow cytometry. A representative histogram indicating the geometric mean fluorescent intensity (gMFI) value for
each condition is shown. Bar graphs represent RBD or S1 binding relative to normoxia. Error bars represent SEM and asterisks
represent p values (*≤.05; **<.01; ***<.001). Abbreviations: SAV-PE: Streptavidin-phycoerythrin; Nx: normoxia (21% O2); Hx:
hypoxia (1% O2).
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In this study, we consider two different and comp-
lementary cellular models. First, Vero E6 cells, a
widely used cell type in SARS-CoV-2 biology research
because of its expression of ACE2, NRP1 and
TMPRSS2 factors, which are components of the cellu-
lar machinery that allow the entry of SARS-CoV-2
into host target cells. Second, NCI-H460 human
lung epithelial cells, which lack the expression of
ACE2 and NRP1 and as such, do not get infected by
pseudotyped viral particles expressing the spike of
SARS-CoV-2, but permits the binding of the spike
and RBD to cellular HS [11,37]. This dual approach
allowed us to investigate the mechanism underlying
the observed reduction of RBD binding and
infectivity.
Using the Vero E6 model we showed that pro-
longed hypoxia reduces the expression levels of cell
surface ACE2 and NRP1, resulting in a reduced
Figure 2. Hypoxia decreases ACE2 and NRP1 protein levels on Vero E6 cells. (a) Relative ACE2 gene expression on Vero E6 and NCI-
H460 measured by Q-PCR (n = 3, unpaired t test). (b) (Left) Western blot of HIF-1α, ACE2 and β-actin on NCI-H460 and Vero E6 cells
cultured under normoxia (21% O2) or hypoxia (1% O2) for the indicated time points. (Right) Relative quantification of ACE2 protein
expression by densitometry (n = 2, one-way ANOVA). (c) Relative gene expression of PGK1 (left) and ACE2 (right) on Vero E6 cells
cultured under normoxia or hypoxia for 24 h (n = 3, unpaired t test). (d ) (Left) Western blot of HIF-1α, NRP1, TMPRSS2 and β-tubu-
lin on Vero E6 and NCI-H460 cells cultured under normoxia or hypoxia for 48 h. (Right) Relative quantification of NRP1 and
TMPRSS2 proteins by densitometry (n = 3, 2-way ANOVA). Error bars represent SEM and asterisks represent p values (*≤.05;
***<.001; ****<.0001).
Figure 3. Hypoxia prevents the infection of Vero E6 cells with pseudotyped viral particles expressing the spike protein of
SARS-CoV-2. (a) Dot plots representing the infection rate of Vero E6 cells exposed to normoxia (21% O2) or hypoxia (1% O2)
measured by flow cytometry (ZsGreen expression) 48 h after addition of the pseudotyped viral particles (n = 6 independent exper-
iments, unpaired t test). Gating strategy was based on uninfected cells. Bar graphs represent infectivity relative to normoxia.
(b) NCI-H460 cells are not infected by pseudotyped viral particles. Error bars represent SEM and asterisks represent p values
(**** < 0001).
1070 E. Prieto-Fernández et al.
susceptibility to infection by pseudotyped viral par-
ticles expressing the spike of SARS-CoV-2. We have
not observed changes in the expression of TMPRSS2
under hypoxia. Previous studies suggest that the
expression of ACE2 under hypoxia is context depen-
dent [21–25]. Hypoxia exposure time is one of the
variables that influence ACE2 levels. We show that
acute hypoxia (24 h) can induce a transient increase
in ACE2 expression, probably mediated by the bind-
ing of HIF-1α to the hypoxia response elements
found in the ACE2 promoter [22,38]. However,
chronic hypoxia (48 h) leads to a significant reduction
of ACE2 and HIF-1α levels on Vero E6 cells. In line
with these findings, a recent study shows that hypoxia
reduces the protein levels of ACE2 on several cell lines
[38].
Cellular HS is known to cooperate with the
entry receptor ACE2 as an attachment factor,
facilitating the initial capture of viral particles by
the cellular glycocalyx [5]. We used NCI-H460
human lung epithelial cells to disentangle the con-
tribution of cellular HS to the observed reduction
of infection under hypoxia on an ACE2-indepen-
dent manner.
First, we confirmed that the RBD binds to HS
expressed on target cells by blocking this interaction
with lactoferrin. Vero E6 cells are less sensitive than
NCI-H460 cells to the blockade exerted by low doses
of lactoferrin. This difference could be attributed to
the interaction of RBD with other cellular components
that are absent in NCI-H460 cells, such as ACE2 and
NRP1. These findings prompted us to use NCI-H460
Figure 4. Lactoferrin blocks the binding of RBD to the surface of epithelial cells. (a and b) Binding of RBD to Vero E6 (a) (n = 2
independent experiments, one-way ANOVA) or NCI-H460 (b) (n = 3 independent experiments, one-way ANOVA) cells cultured
under normoxia (21% O2) for 48 h measured by flow cytometry after incubation with increasing doses of lactoferrin. A represen-
tative flow cytometry histogram indicating the gMFI value for each condition is shown. Error bars represent SEM and asterisks
represent p values (**<.01; ***<.001; ****<.0001).
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cells as a model to assess the effect of hypoxia on the
levels of cellular HS and its interaction with the
spike of SARS-CoV-2.
We showed that hypoxia leads to a significant
reduction of the cellular pool of HS on NCI-H460
cells. Interestingly, syndecan-1, which is expressed in
the lung [10], is responsible for this decrease under
hypoxia. We confirmed this finding by measuring
the binding of RBD to cells expressing different
amounts of syndecan-1. We then wanted to ascertain
if HIF-1α was responsible for the reduction of the
expression of syndecan-1 observed under hypoxia at
both transcriptional and protein expression levels.
Ablation of HIF-1α in NCI-H460 cells demonstrated
that HIF-1α is necessary for the inhibition of synde-
can-1 expression under hypoxia. Moreover, deletion
of HIF-1α results in an increase of cellular HS levels
and higher binding capacity of RBD to hypoxic
NCI-H460 cells.
Together, these results indicate that the hypoxia
response governed by HIF-1α in the host target cells
leads to a protective effect against SARS-CoV-2 infec-
tion. In this context, the administration of HIF prolyl-
hydroxylase (PHD) inhibitors that result in the accumu-
lation of HIF-1α may serve as a potential treatment to
limit the initial attachment and entry of the virus into
host cells [38,39]. It should be noted that as the infection
progresses into COVID-19 disease, exacerbated inflam-
matory responses contribute to severity. Inflammation
and the response to hypoxia are closely related processes
that coexist in certain microenvironments [40,41].
Macrophages are important mediators of lung inflam-
mation during COVID-19 disease [42]. As a result of
hypoxia in the lung, elevatedHIF-1α activity on immune
innate cells contributes to severity [43,44]. In this scen-
ario, promoting systemic HIF-1α activity through
pharmacological intervention in severe COVID-19
patients might be detrimental.
Figure 5. Hypoxia decreases the total level of heparan sulfate on the surface of epithelial cells. (a and b) Total heparan sulfate
levels on Vero E6 (a) and NCI-H460 (b) cells cultured under normoxia (21% O2) or hypoxia (1% O2) for 24 h, measured by flow
cytometry. (c) Expression of the syndecan family members on NCI-H460 cells cultured under normoxia or hypoxia for 24 h. Repre-
sentative flow cytometry histograms including gMFI values are shown. Bar graphs represent syndecan expression levels under
hypoxia relative to normoxia (n = 2 independent experiments, 2-way ANOVA). Error bars represent SEM and asterisks represent
p values (*≤ .05; ****≤.0001).
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In summary, in this study we show that hypoxia
decreases the binding of the spike of SARS-CoV-2 to
epithelial cells by at least two different mechanisms:
(1) decreasing the level of ACE2 and NRP1 expression;
and (2) reducing the total amount of cellular HS
(attachment factor) and syndecan-1 on the cell surface
of epithelial cells.
Limitations of the study
All experiments presented here have been performed
in vitro with immortalized cell lines. The significance
of these findings at physiopathological oxygen levels
in vivo remains unexplored. In this context, the use
of humanized mouse models and real SARS-CoV-2
virus would reinforce the findings of this study.
Figure 6. Hypoxia reduces the binding of RBD to NCI-H460 epithelial cells by downregulating syndecan-1 expression on a HIF-1α-
dependent mechanism. (a) (Left) Gating strategy followed to select cells expressing high (SDC1High) or low (SDC1Low) levels of
syndecan-1 under normoxia. (Right) Representative flow cytometry histogram showing the binding of RBD to SDC1High (green)
or SDC1Low (blue) cell populations (n = 2 independent experiments). gMFI values are shown. (b) (Left) A representative histogram
showing the percentage of cells expressing syndecan-1 in the SDC1-KO or control cells. (Right) Binding of RBD to SDC1-KO cells
normalized to control cells (n = 2 independent experiments). (c) Relative gene expression of PGK1 (left) and SDC1 (right) on NCI-
H460 cells cultured under normoxia or hypoxia for 24 h (n = 3, unpaired t test). (d ) Western blot showing the lack of HIF-1α protein
in HIF1-KO NCI-H460 cells cultured under hypoxia for 24 h. (e) Syndecan-1 expression on HIF1-KO NCI-H460 cells cultured under
normoxia or hypoxia for 24 h, gMFI values are shown. (f and g) Total heparan sulfate level ( f ) and RBD binding (g) on HIF1-KO NCI-
H460 cells (n = 2 independent experiments, unpaired t test) cultured under hypoxia for 24 h, gMFI values are shown. Representa-
tive flow cytometry histograms including gMFI values are shown. Error bars represent SEM and asterisks represent p values (*≤.05;
**<.01; ***<.001).
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